Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.
Cross-sectional study
Fatigue
Hodgkin lymphoma
Long-term survivors
Non-Hodgkin lymphomas
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
02 Jul 2019
02 Jul 2019
Historique:
received:
25
09
2018
accepted:
23
06
2019
entrez:
4
7
2019
pubmed:
4
7
2019
medline:
21
8
2019
Statut:
epublish
Résumé
Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL). Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations. Two cross-sectional studies were conducted in 2009-2010 (HL) and in 2015 (NHL) in survivors enrolled in European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and Lymphoma Study Association (LYSA) trials. The same protocol and questionnaires were used in both studies including the Multidimensional Fatigue Inventory (MFI) tool to assess fatigue and a checklist of health disorders. Multivariate linear regression models were used in the two populations separately to assess the influence of time since diagnosis and primary treatment, age, gender, education level, cohabitation status, obesity and health disorders on fatigue level changes. Fatigue level changes were compared to general population data. Overall, data of 2023 HL and 1619 NHL survivors with fatigue assessment available (99 and 97% of cases, respectively) were analyzed. Crude levels of fatigue were similar in the two populations. Individuals who reported health disorders (61% of HL and 64% of NHL) displayed higher levels of fatigue than those who did not (P < 0.001). HL survivors showed increasing fatigue level with age while in NHL survivors mean fatigue level remained constant until age 70 and increased beyond. HL survivors showed fatigue changes with age higher than those of the general population with health disorders while NHL survivors were in between those of the general population with and without health disorders. Among lymphoma survivors progressive increase of fatigue level with time since treatment completion is a distinctive feature of HL. Our data suggest that changes in fatigue level are unlikely to only depend on treatment complications and health disorders. Investigations should be undertaken to identify which factors including biologic mechanisms could explain why a substantial proportion of survivors develop high level of fatigue.
Sections du résumé
BACKGROUND
BACKGROUND
Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL). Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations.
METHODS
METHODS
Two cross-sectional studies were conducted in 2009-2010 (HL) and in 2015 (NHL) in survivors enrolled in European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and Lymphoma Study Association (LYSA) trials. The same protocol and questionnaires were used in both studies including the Multidimensional Fatigue Inventory (MFI) tool to assess fatigue and a checklist of health disorders. Multivariate linear regression models were used in the two populations separately to assess the influence of time since diagnosis and primary treatment, age, gender, education level, cohabitation status, obesity and health disorders on fatigue level changes. Fatigue level changes were compared to general population data.
RESULTS
RESULTS
Overall, data of 2023 HL and 1619 NHL survivors with fatigue assessment available (99 and 97% of cases, respectively) were analyzed. Crude levels of fatigue were similar in the two populations. Individuals who reported health disorders (61% of HL and 64% of NHL) displayed higher levels of fatigue than those who did not (P < 0.001). HL survivors showed increasing fatigue level with age while in NHL survivors mean fatigue level remained constant until age 70 and increased beyond. HL survivors showed fatigue changes with age higher than those of the general population with health disorders while NHL survivors were in between those of the general population with and without health disorders.
CONCLUSIONS
CONCLUSIONS
Among lymphoma survivors progressive increase of fatigue level with time since treatment completion is a distinctive feature of HL. Our data suggest that changes in fatigue level are unlikely to only depend on treatment complications and health disorders. Investigations should be undertaken to identify which factors including biologic mechanisms could explain why a substantial proportion of survivors develop high level of fatigue.
Identifiants
pubmed: 31266501
doi: 10.1186/s12955-019-1186-x
pii: 10.1186/s12955-019-1186-x
pmc: PMC6604328
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115Subventions
Organisme : Ligue Contre le Cancer
ID : 2014
Organisme : Lance Armstrong Foundation
ID : 2003
Organisme : René Vogels Stichting (NL)
ID : 2009
Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
ID : AAP-2012-20
Références
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563
Clin Exp Immunol. 1977 Jun;28(3):389-93
pubmed: 302164
Leuk Lymphoma. 2015;56(12):3306-14
pubmed: 25827172
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Acta Oncol. 2019 May;58(5):753-762
pubmed: 30696351
Lancet Oncol. 2016 Oct;17(10):1453-1462
pubmed: 27612583
Support Care Cancer. 2016 Dec;24(12):5015-5023
pubmed: 27460016
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):465-71
pubmed: 17418962
Health Qual Life Outcomes. 2016 Jul 29;14(1):114
pubmed: 27473596
Cancer Manag Res. 2017 Jan 31;9:1-10
pubmed: 28203105
Br J Cancer. 2014 May 27;110(11):2796-803
pubmed: 24691420
Histopathology. 2017 Feb;70(3):442-455
pubmed: 27632954
Acta Oncol. 2017 Feb;56(2):288-294
pubmed: 28077017
Acta Oncol. 2019 May;58(5):690-699
pubmed: 30696346
Ann Hematol. 2013 Aug;92(8):1023-32
pubmed: 23728609
Lancet Oncol. 2009 Dec;10(12):1160-70
pubmed: 19828373
Bull Cancer. 2017 Mar;104(3):221-231
pubmed: 28214006
J Pain Symptom Manage. 2017 Jan;53(1):67-84.e7
pubmed: 27720787
Biol Res Nurs. 2015 May;17(3):237-47
pubmed: 25304131
Tumori. 2010 Jul-Aug;96(4):594-600
pubmed: 20968140
Cancer. 2019 Jul 1;125(13):2291-2299
pubmed: 30901086
J Clin Oncol. 2012 Nov 1;30(31):3854-63
pubmed: 23008303
J Adolesc Young Adult Oncol. 2017 Sep;6(3):470-476
pubmed: 28837384
Arch Med Res. 2014 Jul;45(5):417-31
pubmed: 24937173
J Aging Res. 2014;2014:403253
pubmed: 24693429
Br J Cancer. 1996 Nov;74(10):1674-9
pubmed: 8932354
Eur J Cancer. 2003 Jan;39(1):57-63
pubmed: 12504659
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Haematologica. 2013 Mar;98(3):479-86
pubmed: 22929981
J Pain Symptom Manage. 2016 Nov;52(5):695-708.e4
pubmed: 27664835
Cancer. 2006 Feb 15;106(4):751-8
pubmed: 16400678
BMC Cancer. 2018 Sep 10;18(1):880
pubmed: 30200906
Ann Oncol. 2005 Dec;16(12):1949-55
pubmed: 16227316
J Clin Oncol. 2014 Jun 10;32(17):1840-50
pubmed: 24733803
Br J Cancer. 2007 Sep 3;97(5):612-8
pubmed: 17653075
Psychooncology. 2007 Sep;16(9):787-95
pubmed: 17086555
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
J Epidemiol Community Health. 2000 Nov;54(11):827-33
pubmed: 11027196